Navigation Links
Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease
Date:11/7/2007

g the course of vascular disease potentially by increasing inflammation in the arterial wall thus leading to exacerbation of atherosclerosis, which could reduce blood supply to target limbs and organs.

"The conclusive data obtained from this well-powered and well-executed study provides a compelling argument that C. pneumoniae does not play a role in PAD that is modifiable by anti-bacterial therapy. Walking impairment in PAD patients remains a significant unmet medical need, but anti-chlamydial therapy does not appear to be the solution," Dr. Jaff said.

About ActivBiotics, Inc.

ActivBiotics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of inflammatory diseases and bacterial infections. For more information on ActivBiotics, Inc., please visit our web site http://www.activbiotics.com.

Safe Harbor Statement

This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words "may," "believes," "will", "expects," "anticipates" or the negation thereof, or similar expressions, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of ActivBiotics, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. For those statements, ActivBiotics, Inc. claims the protection of the safe harbor for forward-looking statemen
'/>"/>

SOURCE ActivBiotics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... (NYSE: RMD ) today announced results for its ... $423.0 million, a 10 percent increase compared to the quarter ... constant currency basis). Net income was $91.2 million, an increase ... 2013. Diluted earnings per share for the quarter were $0.64, ...
(Date:1/22/2015)... Jan. 22, 2015  Bio-Techne Corporation (NASDAQ: TECH ... first member of the new Simple Plex platform through ... launch represents the re-branding of the previously acquired CyPlex ... platform is a transformative immunoassay technology which integrates an ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... 24, 2012 Marking a major milestone for ... a developer of oral drug delivery systems, announced today that ... Australian Patent Office. The patent covers an important part of ... of peptides. Oramed,s portfolio now consists of one issued patent ...
... Jan. 24, 2012  LoneStar Heart Inc., based here, today ... and Mark Maciejewski to the company,s board of directors. ... the board for LoneStar Heart; Frank Ahmann, the company,s ... executive officer of Vessix Vascular, Inc.; and Eric N. ...
Cached Medicine Technology:Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Company's Core Technology in Oral Delivery of Proteins 2LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors 2LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors 3
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
(Date:1/22/2015)... IPSWICH, Mass. (PRWEB) January 22, 2015 ... Association (AMA) are expanding their relationship in an effort ... journals around the world. While EBSCO has long made AMA ... as a sales agent for The JAMA Network. ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store ... announces its latest collection of wedding dresses , and ... issue is the wedding dress on your big day; the ... life. Every bride wants to find the most suitable wedding ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance of ... the costs of an auto insurance policy . , Clients ... prices for their vehicle insurance policies. The safety a vehicle offers ... Because of this, drivers should always carry a first aid ...
Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... become less expensive and easier in India as a ... detected with the help of polyfex stent, and Fuji ... gastrointestinal cancer claiming too many lives in the country, ... (SGEI) Randhir Sud. ,The cost of ...
... Academy of Sciences, the Chinese Academy of Sciences and the ... unique conference to apprise the world of the progress made ... the light of epidemics like SARS, the H5N1 bird flu ... ,More than a 100 scientists from China, the ...
... Indian origin to receive a license to practice privately in Germany’s ... sees as many as 100 patients per day starting from 7:30 ... practice is estimated at US$ 5 million. // ,What ... has happened in a ‘non-immigration country’ that permits expatriate doctors, but ...
... to stay has made it necessary for health teams to ... University Medical Center has pioneered the use of a baby ... quickly to infants in distress from any chemical weapons attacks ... Health and the Health Resources and Services Administration (HRSA) has ...
... Indian State of Kerala leads the rest of the nation. The ... life expectancy, infant mortality and birth rate are concerned. //The birth ... it is at 24.80 for the entire nation. Likewise, the death ... country and infant mortality is at 11, far lower than the ...
... medical officer, Sir Liam Donaldson, has announced the introduction ... programme , with a motive to prevent children from ... ,The pneumococcal infection, upon entering the blood stream, ... (blood poisoning) and pneumonia. Almost 50 young lives under ...
Cached Medicine News:Health News:East And West Meet Under The Aegis of NY Academy Of Sciences' 2Health News:Pneumococcal Vaccine: Childhood Immunization Programme has a new recruit 2
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 0.6% agarose....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride, 1.5% agar....
1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride, 7.5% Glycerol....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Medicine Products: